読み込み中
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
前日終値
$27.26
+$1.02 · +3.89%
日中の時刻はETです。市場データは遅延する場合があります。
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
日中レンジ
現在 $27.26
52週レンジ
現在 $27.26
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
52
適正価値
センチメント
37
弱気
リスク
52
やや高いリスク
モメンタム
64
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
日中レンジ
現在 $27.26
52週レンジ
現在 $27.26
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上高 | 1000万 USD | 500万 USD | 5000万 USD | — |
| 売上原価 | — | 1.39億 USD | — | 6168.9万 USD |
| 粗利益 | 1000万 USD | −1.34億 USD | 5000万 USD | −6168.9万 USD |
| 研究開発 | 1.68億 USD | 1.39億 USD | 6003.3万 USD | 6268.9万 USD |
| 販売・一般管理 | 5332.2万 USD | 2974.9万 USD | 1711.4万 USD | 1351万 USD |
| 営業費用 | 2.21億 USD | 2974.9万 USD | 8714.7万 USD | 1451万 USD |
| 受取利息 | 1215.1万 USD | — | — | — |
| 支払利息 | 732.7万 USD | — | — | — |
| 減価償却費と償却費 | 5.6万 USD | 13.7万 USD | 11.3万 USD | 7.8万 USD |
| 営業利益 | −2.11億 USD | −1.64億 USD | −3714.7万 USD | −7619.9万 USD |
| 純利益 | −3.78億 USD | −1.57億 USD | −3712.4万 USD | −1.19億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2880.35万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2759.61万0.28%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM2485.56万0.03%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1422.43万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO870.97万0.06%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB694.35万0.07%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA636.72万0.03%218.24億 USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO529.14万0.03%180億 USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
